Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
Arch Neurol
; 62(2): 258-64, 2005 Feb.
Article
em En
| MEDLINE
| ID: mdl-15710854
ABSTRACT
BACKGROUND:
Rituximab, an anti-CD20 monoclonal antibody that depletes CD20(+) B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown.OBJECTIVE:
To determine the effect of rituximab on cerebrospinal fluid B cells in patients with multiple sclerosis.DESIGN:
Four patients with primary progressive multiple sclerosis were treated with rituximab. Cerebrospinal fluid and peripheral blood B-cell subsets were identified by flow cytometry from each patient before and after rituximab treatment.RESULTS:
The B cells in cerebrospinal fluid were not as effectively depleted as their peripheral blood counterparts. Rituximab treatment temporarily suppressed the activation state of B cells in cerebrospinal fluid. The residual B cells underwent expansion after rituximab treatment.CONCLUSION:
The effect(s) of rituximab on the cerebrospinal fluid B-cell compartment is limited in comparison with the effect(s) on the B cells in the periphery, but this finding will need to be confirmed in a larger group of MS patients.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Linfócitos B
/
Antígenos CD20
/
Esclerose Múltipla Crônica Progressiva
/
Anticorpos Monoclonais
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article